Elevance Health Inc.

(New York Stock Exchange)
Back to all articles
Bullish +55

Elevance Health stock gains on fresh analyst price target revisions

AI-generated analysis

πŸ“ˆ Elevance Health shares trade near USD 414 with a market capitalization of roughly USD 89.9 billion as of September 18, 2026.

πŸ“Š Analyst price targets range from USD 424 to USD 492, with major firms like TD Cowen and Wells Fargo raising targets above current levels.

πŸ’° The company generates an annualized revenue base of USD 198.7 billion, providing significant bargaining power in provider negotiations.

πŸ“ˆ Earnings per share have grown by approximately 7.2 percent annually over the past five years, outpacing peer-group averages.

🏦 Return on invested capital stands at roughly 26 percent, indicating robust capital allocation and efficient use of shareholder funds.

πŸ“‰ The stock trades at a price-to-earnings ratio of around 18.34 times forward earnings, reflecting a mid-teens valuation.

πŸ’Έ Elevance Health offers a dividend yield of about 1.66 percent, appealing to long-term investors seeking income potential.

πŸ“‰ The stock has posted a one-month return of 4.6 percent, placing it among surging stocks on various watchlists.

⚠️ Analysts note that the managed-care sector faces risks from regulatory changes to Medicare and Medicaid reimbursement structures.

⚠️ Competitive dynamics and rising medical costs could compress margins if pricing fails to fully offset these increases.

Bullish Signals
  • Major analyst firms including TD Cowen, Truist Securities, and Wells Fargo have raised or maintained Buy/Overweight ratings with price targets ranging from USD 465 to USD 492.
  • The company has delivered a one-month stock return of 4.6 percent, indicating sustained positive momentum beyond single-session moves.
  • Earnings per share have grown by approximately 7.2 percent annually over the past five years, demonstrating consistent bottom-line progress.
  • Return on invested capital is cited at roughly 26 percent, reflecting robust capital allocation and efficient use of shareholder funds.
  • The company generates a massive annualized revenue base of USD 198.7 billion, providing considerable bargaining power when negotiating reimbursement rates.
Risk Factors
  • RBC Capital lowered its price target to USD 424 from USD 439, signaling a slightly more cautious stance despite maintaining a Sector Perform rating.
  • The managed-care sector is heavily exposed to regulatory changes and public policy decisions around Medicare, Medicaid, and individual marketplace plans.
  • Rising medical costs combined with competitive pressure on premiums could compress margins if pricing does not fully offset these increases.
Full Analysis
Elevance Health shares traded around USD 414 on September 18, 2026, following a series of analyst price target revisions that reflect mixed but generally constructive sentiment. While RBC Capital lowered its target to USD 424 citing caution, major firms like TD Cowen, Truist Securities, and Wells Fargo raised or maintained targets between USD 465 and USD 492, signaling confidence in the company's earnings trajectory and cash generation capabilities. The stock has delivered a one-month return of 4.6 percent, trading at approximately 18 times forward earnings with a dividend yield of 1.66 percent. Fundamentally, Elevance Health generates an annualized revenue base of USD 198.7 billion and has achieved roughly 26 percent return on invested capital over the past five years, demonstrating robust capital allocation and efficient cost management across its large membership base. Analysts highlight that while the company's strong fundamentals support a balanced growth-and-income profile, investors must weigh sector-specific risks including regulatory changes to Medicare and Medicaid plans, as well as competitive pressure on premiums. The consensus view suggests that if Elevance Health can maintain its historical earnings-per-share growth rate of 7.2 percent annually, the stock remains supported by institutional demand despite macroeconomic uncertainties.